Pneumococcal Vaccination Recommendations

Introduction to Pneumococcal Vaccination

The Centers for Disease Control and Prevention (CDC) recommends pneumococcal vaccination starting at age 50, with either PCV20 alone or PCV15 followed by PPSV23 at least 1 year later for all adults ≥50 years, as per the 2023 guidelines 1, 2

For vaccine-naïve patients, the American College of Physicians recommends a single dose of PCV20 for simplicity and broader serotype coverage 3, 4
The CDC advises against coadministering pneumococcal vaccines on the same day, and recommends sequential administration of PCV and PPSV23, with PCV given first 1, 3, 4, 7

Immunocompromised patients, including those with HIV infection, chronic renal failure, or malignancies requiring immunosuppressive treatment, should receive PCV first, then PPSV23 at least 8 weeks later, as recommended by the CDC 6
The Infectious Diseases Society of America recommends that patients with prior vaccination history, such as those who previously received PPSV23 or PCV13, should receive a single dose of PCV20 or PPSV23 at least 1 year after the last dose 3, 5

The newer vaccines, such as PCV15, PCV20, and PCV21, provide broader serotype coverage, addressing the 60-75% of invasive pneumococcal disease caused by the 24 serotypes included in current vaccine formulations, as reported by the CDC 2
The cost-effectiveness of universal PCV13 vaccination decreased significantly from 2014 to 2019, with cost-effectiveness ratios increasing from $65,000 per QALY to $200,000-$560,000 per QALY, according to the CDC 4